Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension
- PMID: 12107398
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension
Abstract
In arterial hypertension, left ventricular (LV) hypertrophy (H) is a prognostically relevant target organ damage associated with systolic and diastolic LV dysfunction. The level of LV dysfunction seems to be related to the degree of myocardial fibrosis. Prognosis of hypertensive patients who have LVH regression appears to be improved. Therefore, LVH regression is an important antihypertensive treatment goal. The renin-angiotensin-aldosterone system is implicated in LVH development and myocardial fibrosis in essential arterial hypertension. Early studies in the 80s and 90s have led expectations that angiotensin converting enzyme (ACE) inhibitors could induce greater LVH regression than other antihypertensive drugs at similar blood pressure reduction. In the late 90s, the double-blind randomized controlled PRESERVE trial (Prospective Randomize Enalapril Study Evaluating Reversal of Ventricular Enlargement) has been designed to evaluate whether the ACE inhibitor enalapril was more effective than nifedipine GITS in regressing LVH and improving LV diastolic dysfunction. The PRESERVE study demonstrated a mildly higher antihypertensive effect of nifedipine GITS than enalapril, which required more frequently association with hydrochlorothiazide to control blood pressure. However, at similar level of blood pressure reduction achieved with enalapril and long-acting nifedipine in association with hydrochlorothiazide or atenolol, both antihypertensive treatments showed similar efficacy in LVH regression and LV diastolic filling improvement.
Similar articles
-
Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.Blood Press Suppl. 1994;2:35-40. Blood Press Suppl. 1994. PMID: 8061844 Review.
-
Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.Kidney Int Suppl. 1997 Oct;61:S74-6. Kidney Int Suppl. 1997. PMID: 9328972 Clinical Trial. No abstract available.
-
Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial.Circulation. 2001 Sep 11;104(11):1248-54. doi: 10.1161/hc3601.095927. Circulation. 2001. PMID: 11551875 Clinical Trial.
-
Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I.J Investig Med. 1997 Dec;45(9):584-91. J Investig Med. 1997. PMID: 9444886
-
Left ventricular hypertrophy: how to influence an important risk factor in hypertension.J Hypertens Suppl. 1998 Jan;16(1):S53-8. J Hypertens Suppl. 1998. PMID: 9534098 Review.
Cited by
-
Melatonin alleviates angiotensin-II-induced cardiac hypertrophy via activating MICU1 pathway.Aging (Albany NY). 2020 Nov 26;13(1):493-515. doi: 10.18632/aging.202159. Epub 2020 Nov 26. Aging (Albany NY). 2020. PMID: 33259334 Free PMC article.
-
Modifiable Risk Factors and Atrial Fibrillation: the Quest for a Personalized Approach.Maedica (Bucur). 2021 Mar;16(1):88-96. doi: 10.26574/maedica.2020.16.1.88. Maedica (Bucur). 2021. PMID: 34221161 Free PMC article.
-
Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy.J Mol Med (Berl). 2006 Jan;84(1):88-96. doi: 10.1007/s00109-005-0718-5. Epub 2005 Nov 11. J Mol Med (Berl). 2006. PMID: 16283142
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous